טוען...
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
In metastatic breast cancer (mBC), the change of human epidermal growth factor receptor 2 (HER2) status between primary and metastatic lesions is widely recognized, however clinical implications are unknown. Our study address the question if relevant differences exist between subjects who preserve t...
שמור ב:
| הוצא לאור ב: | Sci Rep |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Nature Publishing Group UK
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8253801/ https://ncbi.nlm.nih.gov/pubmed/34215766 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-92774-z |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|